ArticleBiochemistry and biophysics reports2025
Heparin suppresses FoxO1/pFoxO1 signaling axis in vascular smooth muscle cells.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The atherosclerosis process relates to the dysfunction of different cells in the plaque microenvironment. The vascular smooth muscle cells (VSMCs) play an important role in atherosclerosis. Since the FoxO family is reported to control cell growth, thus the aim of this study was to investigate the effects of Heparin, Betulinic acid, and Ibrutinib on the FoxO1/pFoxO1 axis in vascular smooth muscle cells. Methods: The VSMCs were cultured in DMEM-F12 medium and, were treated with Heparin (30IU), Betulinic acid (60 μM), and Ibrutinib (2 μM) in the 24 and 48-h periods. The FoxO1 gene expression level was identified using the RT-qPCR technique. The FoxO1 and pFoxO1 protein values were measured by the Western blot technique. Results: The FoxO1 gene expression levels were reduced significantly in the cellular groups treated with Heparin, Betulinic acid, and Ibrutinib (P < 0.05) in both periods. Moreover, the pFoxO1 and FoxO1 protein values were decreased by Heparin, and Betulinic acid in the VSMCs. Conclusion: Heparin suppressed the FoxO1/pFoxO1 signaling axis in vascular smooth muscle cells (VSMCs). Furthermore, it modulated the effects of Betulinic acid and Ibrutinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.